Marksans Pharma reports 17% rise in Q4 consolidated net profit

20 May 2025 Evaluate

Marksans Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2025.

The company has reported 13.94% rise in its net profit at Rs 37.59 crore for the quarter under review as compared to Rs 32.99 crore for the same quarter in the previous year. The total income of the company increased by 29.39% at Rs 307.17 crore for Q4FY25 as compared to Rs 237.39 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 16.86% rise in its net profit at Rs 90.73 crore for fourth quarter ended March 31, 2025 as compared to Rs 77.64 crore for the same quarter in the previous year. The total income of the company increased by 25.75% at Rs 724.98 crore for Q4FY25 as compared to Rs 576.54 crore for the corresponding quarter previous year.

For the year ended March 31, 2025, the company has reported 40.75% rise in its net profit at Rs 188.27 crore as compared to Rs 133.76 crore for the previous year. The total income of the company increased by 35.93% at Rs 1,244.21 crore for year under review as compared to Rs 915.35 crore for year ended March 31, 2024.

For the year ended March 31, 2025, on the consolidated basis, the company has reported 21.51% rise in its net profit at Rs 382.62 crore as compared to Rs 314.90 crore for the previous year. The total income of the company increased by 20.89% at Rs 2,693.22 crore for year under review as compared to Rs 2,227.83 crore for year ended March 31, 2024.

Marksans Pharma Share Price

183.95 -3.95 (-2.10%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×